4.6 Article

A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma

期刊

BMC CANCER
卷 22, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s12885-022-09781-0

关键词

Melanoma; Skin neoplasms; Neoplasm staging; Ontario; Survival analysis; Prognosis; Cohort studies

类别

资金

  1. Ontario Institute for Cancer Research by the Government of Ontario [IA-035]
  2. Canadian Institutes of Health Research Operating Grant [MOP 137022]

向作者/读者索取更多资源

This study validates the effectiveness of the 8th edition TNM melanoma staging system (TNM8) using a large population-based database. The results show that TNM8 provides more even separation of stage subgroups and improves predictive ability compared to the 7th edition TNM (TNM7).
Background The 8(th) edition UICC/AJCC TNM8 (Tumour, Nodes, Metastasis) melanoma staging system introduced several modifications from the 7(th) edition (TNM7), resulting in changes in survival and subgroup composition. We set out to address the limited validation of TNM8 (stages I-IV) in large population-based datasets. Methods This retrospective cohort-study included 6,414 patients from the population-based Ontario Cancer Registry diagnosed with cutaneous melanoma between January 1, 2007 and December 31, 2012. Kaplan-Meier curves estimated the melanoma-specific survival (MSS) and overall survival (OS). Cox proportional hazard models were used to estimate adjusted hazard ratios for MSS and OS across stage groups. The Schemper-Henderson measure was used to assess the variance explained in the Cox regression. Results In our sample, 21.3% of patients were reclassified with TNM8 from TNM7; reclassifications in stage II were uncommon, and 44.1% of patients in stage III were reclassified to a higher subgroup. Minimal changes in MSS curves were observed between editions, but the stage IIB curve decreased and the stage IIIC curve increased. For TNM8, Stage I (n = 4,556), II (n = 1,206), III (n = 598), and IV (n = 54) had an estimated 5-year MSS of 98.4%, 82.5%, 66.4%, and 14.4%, respectively. Within stage III, IIIA 5-year MSS was 91.7% while stage IIID was 23.5%. HRs indicated that TNM8 more evenly separates subgroups once adjusted for patient- and disease-characteristics. The variance in MSS explained by TNM7 and TNM8 is 18.9% and 19.7%, respectively. Conclusion TNM8 performed well in our sample, with more even separation of stage subgroups and a modest improvement in predictive ability compared to TNM7.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据